Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955123 | 0.89 | HPGD (0.50) | ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL8127138 | 0.83 | KMT2A (0.54) | ALDH1A1MEN1KMT2AMAPTMAOB | |
| SCHEMBL12451865 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL653251 | 0.81 | ALOX15 (0.65) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL8234368 | 0.81 | MAPT (0.59) | ALDH1A1MEN1KMT2AMAPTMAOB | |
| SCHEMBL9320698 | 0.81 | LTA4H (0.50) | ALDH1A1MAPT | |
| SCHEMBL10858118 | 0.81 | LMNA (0.58) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL4115419 | 0.80 | PTGS2 (0.57) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| SCHEMBL24261132 | 0.79 | HPGD (0.44) | ALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL12909782 | 0.79 | L3MBTL1 (0.68) | ALDH1A1MAPTPOLBMAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134751-A1 | TUBULIN-SRC DUAL-TARGET INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444426-A | tubulin-Src dual-target inhibitors and uses thereof | 武汉人福创新药物研发中心有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3235799-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| WO-2016098899-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | 日産化学工業株式会社 | 2016-06-23 | — | — | WO | disclosed |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R TECH UENO LTD (JP) | 2015-06-18 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-03-10 | — | — | US | disclosed |
| US-7691493-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7691493-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-20070257604-A1 | POLYMERIC COMPOUND AND ORGANIC LUMINESCENCE DEVICE | CANON KABUSHIKI KAISHA (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070257604-A1 | POLYMERIC COMPOUND AND ORGANIC LUMINESCENCE DEVICE | CANON KABUSHIKI KAISHA (JP) | 2007-11-08 | — | — | US | disclosed |
| US-7238435-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238435-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | ALDH1A1 1419/4885MEN1 1922/4885KMT2A 1628/4885 |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | ALDH1A1 141/4885MEN1 4322/4885KMT2A 2805/4885 |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | ALDH1A1 141/4885MEN1 4322/4885KMT2A 2805/4885 |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | OR10J3, CYP1B1, CBR3 | ALDH1A1 517/4885MEN1 3264/4885KMT2A 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.